Diagnostic Value of Quantitative Contrast-Enhanced Ultrasound in Comparison to Endoscopy in Children With Crohn's Disease.
Crohn's disease
PCDAI
children
contrast-enhanced ultrasound
endoscopy
fecal Calprotectin
Journal
Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
ISSN: 1550-9613
Titre abrégé: J Ultrasound Med
Pays: England
ID NLM: 8211547
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
revised:
04
05
2022
received:
02
01
2022
accepted:
02
06
2022
pubmed:
25
6
2022
medline:
22
12
2022
entrez:
24
6
2022
Statut:
ppublish
Résumé
Quantitative contrast-enhanced US (CEUS) provides objective evaluation of bowel wall perfusion and has been reported as a useful method for evaluating Crohn's disease (CD) activity in children. We tested its' diagnostic accuracy in comparison to endoscopy and evaluated its' usefulness in comparison to Pediatric Crohn's Disease Activity Index (PCDAI) and fecal Calprotectin (FC). Children with CD and thickened bowel wall on abdominal US were prospectively enrolled. Disease activity was evaluated with quantitative CEUS, PCDAI and FC and compared to a simple endoscopic score for Crohn's disease (SES-CD). Spearman's correlation and Cohen's kappa statistic between the SES-CD and other disease activity measures were performed and diagnostic accuracies calculated. 36 children 3.5-18 years old (mean age 14 years) were included. The quantitative CEUS had 78.57% sensitivity (95%CI 0.59-0.92), 100% specificity (95%CI 0.63-1.0) and 83.33% diagnostic accuracy (95% CI 0.67-0.94). The concordance remission agreement with endoscopy was substantial for quantitative CEUS and PCDAI (quantitative CEUS: κ = 0.62; 95% CI 0.363-0.877; PCDAI: κ = 0.615; 95% CI 0.311-0.920), but only fair for FC (κ = 0.389; 95% CI 0.006-0.783). Correlation between all measures and endoscopy was moderate and statistically significant (quantitative CEUS: r Quantitative CEUS has a potential of becoming a complementary method for evaluation of CD activity in children due to its' high specificity in comparison to endoscopy. Lower sensitivity makes it deficient as a single measure and further management should be guided by PCDAI and FC results as well.
Substances chimiques
Leukocyte L1 Antigen Complex
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
193-200Informations de copyright
© 2022 American Institute of Ultrasound in Medicine.
Références
Van Rheenen PF, Aloi M, Assa A, et al. The medical Management of Paediatric Crohn's disease: an ECCO-ESPGHAN guideline update. J Crohns Colitis 2021; 15:171-194.
Zacharopoulou E, Craviotto V, Fiorino G, et al. Targeting the gut layers in Crohn's disease: mucosal or transmural healing? Expert Rev Gastroenterol Hepatol 2020; 14:775-787.
Turner D, Levine A, Walters TD, et al. Which PCDAI version best reflects intestinal inflammation in pediatric Crohn disease? J Pediatr Gastroenterol Nutr 2017; 64:254-260.
Ma C, Battat R, Parker CE, Khanna R, Jairath V, Feagan BG. Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn's disease? Expert Rev Gastroenterol Hepatol 2019; 13:319-330.
Carman N, Tomalty D, Church PC, et al. Canadian children inflammatory bowel disease network: a joint Partnership of Canadian Institutes of Health Research and the children with intestinal and liver disorders foundation. Clinical disease activity and endoscopic severity correlate poorly in children newly diagnosed with Crohn's disease. Gastrointest Endosc 2019; 89:364-372.
Simon EG, Wardle R, Thi AA, Eldridge J, Samuel S, Moran GW. Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn's disease? A systematic review. Intest Res 2019; 17:160-170.
Queliza K, Wang MK, Kellermayer R. Compliance with fecal calprotectin testing in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2018; 66:932-933.
Ponorac S, Gošnak RD, Urlep D, Ključevšek D. Contrast-enhanced ultrasonography in the evaluation of Crohn disease activity in children: comparison with histopathology. Pediatr Radiol 2021; 51:410-418.
Gokli A, Dillman JR, Humphries PD, et al. Contrast-enhanced ultrasound of the pediatric bowel. Pediatr Radiol 2021; 51:2214-2228.
Daperno M, Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004; 60:505-512.
Turner D, Griffiths AM, Walters TD, et al. Appraisal of the pediatric Crohn's disease activity index on four prospectively collected datasets: recommended cutoff values and clinimetric properties. Am J Gastroenterol 2010; 105:2085-2092.
Shaoul R, Day AS. An overview of tools to score severity in pediatric inflammatory bowel disease. Front Pediatr 2021; 9:615216.
Reenaers C, Bossuyt P, Hindryckx P, Vanpoucke H, Cremer A, Baert F. Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice. United Eur Gastroent 2018; 6:1117-1125.
Shaoul R, Sladek M, Turner D, et al. ESPGHAN Porto IBD group. Limitations of fecal calprotectin at diagnosis in untreated pediatric Crohn's disease. Inflamm Bowel Dis 2012; 18:1493-1497.
Zubin G, Peter L. Predicting endoscopic Crohn's disease activity before and after induction therapy in children: a comprehensive assessment of PCDAI, CRP, and fecal calprotectin. Inflamm Bowel Dis 2015; 21:1386-1391.
Lu C, Merrill C, Medellin A, Novak K, Wilson SR. Bowel ultrasound state of the art: grayscale and Doppler ultrasound, contrast enhancement, and Elastography in Crohn disease. J Ultrasound Med 2019; 38:271-288.
Maconi G, Nylund K, Ripolles T, et al. EFSUMB recommendations and clinical guidelines for intestinal ultrasound (GIUS) in inflammatory bowel diseases. Ultraschall Med 2018; 39:304-317.
Gonga W, Guo K, Zheng T, et al. Correlation between endoscopic and histological validated scoring indices in Crohn's disease. Dig Liver Dis 2019; 51:812-817.
Agrawal M, Colombel JF. Treat-to-target in inflammatory bowel diseases, what is the target and how do we treat? Gastrointest Endosc Clin N Am 2019; 29:421-436.
Şerban ED. Treat-to-target in Crohn's disease: will transmural healing become a therapeutic endpoint? World J Clin Cases 2018; 6:501-513.
Ripolle's T, Rausell N, Paredes JM, Grau E, Martínez MJ, Vizuete J. Effectiveness of contrast-enhanced ultrasound for characterisation of intestinal inflammation in Crohn's disease: a comparison with surgical histopathology analysis. J Crohns Colitis 2013; 7:120-128.
Quaia E, De Paoli L, Stock T, Cabibbo B, Casagrande F, Cova MA. The value of small bowel wall contrast enhancement after sulfur hexafluoride filled microbubble injection to differentiate inflammatory from fibrotic strictures in patients with Crohn's disease. Ultrasound Med Biol 2012; 38:1324-1332.
Wilkens R, Hagemann-Madsen RH, Peters DA, et al. Validity of contrast-enhanced ultrasonography and dynamic contrast-enhanced MR enterography in the assessment of transmural activity and fibrosis in Crohn's disease. J Crohns Colitis 2018; 12:48-56.
Dillman JR, Rubin JM, Johanson LA, Moons DS, Higgins PD. Can contrast-enhanced sonography detect bowel wall fibrosis in mixed inflammatory and fibrotic Crohn disease lesions in an animal model? J Ultrasound Med 2017; 36:523-530.
Thimm MA, Cuffari C, Garcia A, Sidhu S, Hwang M. Contrast-enhanced ultrasound and shear wave Elastography evaluation of Crohn's disease activity in three adolescent patients. Pediatr Gastroenterol Hepatol Nutr 2019; 22:282-290.
Mudambi K, Sandberg J, Bass D, Rubesova E. Contrast enhanced ultrasound: comparing a novel modality to MRI to assess for bowel disease in pediatric Crohn's patients. Transl Gastroenterol Hepatol 2020; 5:13.
Cozijnsen MA, Shoham AB, Kang B, et al. Development and validation of the mucosal inflammation non-invasive index for pediatric Crohn's disease. Clin Gastroenterol Hepatol 2020; 18:133-140.